According to the agreement, Terumo purchased 80.1% of the shares of Quirem Medical in addition to its existing 19.9% holding in the company.
The acquired company specialises in the development of microspheres for selective internal radiation therapy (SIRT) for the treatment of liver tumours.
Its QuiremSpheres are considered to be the only commercially available microspheres, containing the radioactive isotope Holmium-166.
The company also develops QuiremScout, a low-dose holmium microsphere that helps in evaluating the biodistribution of microspheres prior to therapy.
Q-Suite, dosimetry software package produced by Quirem Medical, is used to plan QuiremSpheres treatments based on QuiremScout dose imaging. It can be used to confirm SIRT success immediately after the procedure by converting SPECT and MR imaging into absorbed dose distribution.
Quirem Medical’s Holmium SIRT Platform, which comprises the three products, provides physicians with the necessary tools to optimise SIRT outcomes while offering personalised treatment to the patients.
QuiremSpheres, QuiremScout and Q-Suite are CE-Marked and are available in Europe, the Middle East and Africa (EMEA).
Terumo plans to launch the Holmium Platform globally in the next few years as part of the ongoing expansion of its interventional oncology (IO) portfolio.
Terumo Interventional Systems Division chief commercial officer Jim Rushworth said: “The acquisition of Quirem Medical further strengthens our business, expands on our manufacturing and clinical development activities and complements our comprehensive suite of offerings to support our customers.”
Terumo’s current oncology offerings include Progreat microcatheter system, HydroPearl compressible microspheres, LifePearl drug-eluting microspheres and BioPearl biodegradable drug-eluting microspheres.
Quirem Medical CEO Jan Sigger said: “We are very excited with the acquisition of Quirem Medical by Terumo as it will further drive the adoption of our unique product offerings worldwide and accelerate our pace of innovation, reaching more patients that will benefit from our technology.”
In 2015, Terumo invested in Quirem Medical, obtaining the exclusive global distribution rights of its technology.